Randomized phase II study of temozolomide given every 8 hours or daily with either interferon Alfa-2b or thalidomide in metastatic malignant melanoma

Journal of Clinical Oncology

Volumn 21, Issue 13, 2003, Pages 2551-2557

  Danson, S ^a   Lorigan, P ^a   Arance, A ^a   Clamp, A ^a   Ranson, M ^a   Hodgetts, J ^a   Lomax, L ^a   Ashcroft, L ^a   Thatcher, N ^a   Middleton, M R ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; TEMOZOLOMIDE; THALIDOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADVANCED CANCER; ARTICLE; BONE MARROW TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INCREASE; DRUG TOLERABILITY; HEMATOLOGIC DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGED; DISEASE COURSE; DRUG ADMINISTRATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SKIN TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SKIN NEOPLASMS; SURVIVAL; THALIDOMIDE;

EID: 0037676126     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.039     Document Type: Article

References (37)

1. Coleman MP, Babb P, Damiecki P, et al: Cancer survival trends in England and Wales, 1971-1995: Deprivation and NHS region. Studies in Medical and Population Subjects (no. 61). The Stationary Office, London, United Kingdom, 1999, pp 331-342
2. Lee SM, Betticher DC, Thatcher N: Melanoma: Chemotherapy. Br Med Bull 51:609-630, 1995
3. Balch CM, Reintgen DS, Kirkwood JM, et al: Cutaneous melanoma, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 1947-1994
4. Middleton MR, Lorigan P, Owen J, et al: A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen (DBCT) v dacarbazine and interferon (D/I) in advanced melanoma. Br J Cancer 82:1158-1162, 2000
5. Stevens MFG, Hickman JA, Langdon SP, et al: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo[5, 1-d]-1, 2, 3, 5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47:5846-5852, 1987
6. Newlands ES, Blackledge GRP, Slack JA, et al: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287-291, 1992
7. Agarwala SS, Reyderman L, Statkevich P: Pharmacokinetic study of temozolomide penetration into CSF in a patient with dural melanoma. Ann Oncol 9:659a, 1998 (suppl 4)
8. Patel M, McCully C, Godwin K, et al: Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc Am Soc Clin Oncol 14:461, 1995 (abstr)
9. 11C-temozolomide uptake by human recurrent high grade astrocytomas. Br J Cancer 75:1241, 1997 (abstr)
10. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolamide versus dacarbazine in the treatment of patients with advanced metastatic melanoma. J Clin Oncol 18:158-166, 2000
11. Paul MJ, Summers Y, Calvert H, et al: Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 12:175-178, 2002
12. Bleehen NM, Newlands ES, Lee SM, et al: Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910-913, 1995
13. 6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study. Int J Cancer 88:469-473, 2000
14. 6-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 7:2309-2317, 2001
15. Bridgewater J, Gore M: Biological response modifiers in melanoma. Br Med Bull 51:656-677, 1995
16. Falkson C, Falkson G, Falkson H: Improved results with the addition of interferon alpha-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9:1403-1408, 1991
17. Thomson D, Adena M, Macleod G: Interferon alpha-2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma. Melanoma Res 3:133-138, 1993
18. Falkson CI, Ibrahim J, Kirkwood JM, et al: Phase III trial of dacarbazine versus dacarbazine with interferon alfa-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alfa-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 16:1743-1751, 1998
19. Huncharek M, Caubet JF, McGarry R: Single-agent dacarbazine versus combination chemotherapy with or without immunotherapy in metastatic melanoma: A meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 11:75-81, 2001
20. Agarwala SS, Kirkwood JM: Temozolomide in combination with interferon alfa-2b in patients with metastatic melanoma. A phase I dose-escalation study. Cancer 97:121-127, 2003
21. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 91:4082-4085, 1994
22. Saphir A: Jekyll and Hyde: A new license for thalidomide? J Natl Cancer Inst 89:1480-1481, 1997
23. Eisen T, Boshoff C, Mak I, et al: Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 14:17-20, 2000 (suppl 13)
24. Kudva G, Collins BT, Dunphy FR: Thalidomide for malignant melanoma. N Engl J Med 345:1214-1215, 2001
25. Heere-Ress E, Boehm J, Hoeller C, et al: Thalidomide enhances the anti-tumour activity of standard chemotherapy in a human melanoma xenotransplantation model. Proc Am Assoc Cancer Res 43:523, 2002 (abstr 2595)
26. National Cancer Institute: Investigator's Handbook: A Manual for Participants in Clinical Trials of Investigational Agents Sponsored by DCTD, NCI. Bethesda, MD, National Cancer Institute, 1993
27. World Health Organization: The WHO Handbook for Reporting Results of Cancer Treatment. WHO publicaton no. 48. Geneva, Switzerland, World Health Organization, 1979
28. Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751, 1999
29. 6-alkylguanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev 15:279-292, 1988
30. Middleton MR, Kelly J, Goodger S, et al: Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts. Cancer Chemother Pharmacol 45:15-20, 2000
31. Lee SM, Thatcher N, Crowther D, et al: Inactivation of O6-alkyltransferase-DNA-alkyltransferase in human peripheral mononuclear cells by temozolomide. Br J Cancer 69:452-456, 1994
32. Martin MG, Tres A, Crespo C, et al: Phase II multicenter study of temozolomide in combination with interferon alfa-2b in metastatic malignant melanoma. Proc Am Soc Clin Oncol 21:348, 2002 (abstr 1389)
33. Ridolfi R, Romanini A, Sileni VC, et al: Temozolomide plus alpha interferon in metastatic melanoma: Preliminary evaluation of a multicenter phase II study of Italian Melanoma Intergroup. Proc Am Soc Clin Oncol 21:348, 2002 (abstr 1388)
34. Rusthoven JJ, Quirt IC, Iscoe NA, et al: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Cancer Clinical Trials Group. J Clin Oncol 14:2083-2090, 1996
35. Jungnelius U, Ringbourg U, Aamdal S, et al: Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma: A randomized phase III trial. Eur J Cancer 34:1368-1374, 1998
36. Hwu W, Krown SE, Pangeas KS, et al: Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial. J Clin Oncol 20:2610-2615, 2002
37. Hwu WJ, Krown SE, Menell JH, et al: U-temozolomide (TMZ) plus thalidomide in patients with advanced melanoma: A phase II trial. Proc Am Soc Clin Oncol 21:344, 2002 (abstr 1372)